For people who believe eating healthier should be effortless and tasty, The Not Company is a Foodtech, that reinvents animal-based foods using only plants. Unlike traditional food businesses, our company uses technology to recreate the same products we love to eat in a natural, sustainable and affordable way, keeping it functional, easy to use and mouthwateringly delicious.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOCLEAN INNOVATIONS AND REP-L® ANTIMICROBIALS PARTNERS TO LAUNCH A POWERFUL NON-TOXIC BIO-BASED ANTIMICROBIAL PRODUCT LINE

Bioclean Innovations | October 19, 2020

news image

Bioclean Innovations Inc, a Biotech startup focused on innovative antimicrobial solutions to combat disease outbreaks has partnered with rep-L® Antimicrobials, to launch a powerful but non-toxic bio-based antimicrobial product line. Our rep-L-based disinfectants are designed to create a new methodology for addressing the infection control challenges facing the education and long-term health care sectors today. The SARS-CoV-2 virus responsible for the COVID-19 pandemic is one of an increasing...

Read More

MEDTECH, INDUSTRIAL IMPACT

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

news image

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

news image

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More

INDUSTRIAL IMPACT

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS TARGETING

FogPharma | November 22, 2022

news image

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant...

Read More
news image

BIOCLEAN INNOVATIONS AND REP-L® ANTIMICROBIALS PARTNERS TO LAUNCH A POWERFUL NON-TOXIC BIO-BASED ANTIMICROBIAL PRODUCT LINE

Bioclean Innovations | October 19, 2020

Bioclean Innovations Inc, a Biotech startup focused on innovative antimicrobial solutions to combat disease outbreaks has partnered with rep-L® Antimicrobials, to launch a powerful but non-toxic bio-based antimicrobial product line. Our rep-L-based disinfectants are designed to create a new methodology for addressing the infection control challenges facing the education and long-term health care sectors today. The SARS-CoV-2 virus responsible for the COVID-19 pandemic is one of an increasing...

Read More
news image

MEDTECH, INDUSTRIAL IMPACT

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More
news image

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More
news image

INDUSTRIAL IMPACT

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS TARGETING

FogPharma | November 22, 2022

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant...

Read More